Gebon Biotech secures a $30 million strategic equity investment from Sanofi.

Gebobiology announced today that it has received a $30 million strategic equity investment from Sanofi. This round of investment will support the research and development progress of Gebobiology's two core projects, GLB-005 and GLB-007, both of which are expected to become disease-modifying therapies for the treatment of sickle cell disease.